Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, is poised to capitalize on the increasing demand for novel radiotherapeutics. The company’s platform technology uses small molecule targeting to deliver therapeutic radioisotopes aimed at novel targets on a broad range of cancers by binding selectively to peptide receptors that are overexpressed on these tumors. This small molecule technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics. Spun out of Crinetics (Nasdaq: CRNX) in 2021 and financed by 5AM Ventures and Frazier Healthcare, Radionetics is advancing a pipeline of multiple lead drug candidates pursuing first-in-class targets to treat a broad range of cancers. According to commercially available market research reports, the market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. For more information, visit https://radionetics.com. The Senior Accountant will play a critical role in the day-to-day financial operations of Radionetics. This individual will be a key contributor in the month-end close process, manage the accounts payable function, and assist with the technical execution of clinical trial accruals. The ideal candidate is a Big 4-trained CPA who is ready to transition into a hands-on biotech environment, bringing a high level of technical rigor and "audit-ready" documentation to a growing R&D organization. This role reports to the Senior Manager of Accounting and will work closely with the Controller, CFO, and other cross-functional teams.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level